“Reduction in Pruritus Across Indications in Phase 3 Trials of Topical Roflumilast in Patients as Young as 2 Years” (2026) SKIN The Journal of Cutaneous Medicine, 10(2), p. s766. doi:10.25251/94s3pn30.